Unchecked drug price increases hit both patients and hospitals hard. Since 2008, brand name drugs prices have increased 127 percent compared with an 11 percent rise in consumer prices. These increases cut deep into both hospital budgets and services and undermine patient and community health, particularly when patients cannot afford to take their medicines. These increases are simply unsustainable. This week, we joined the Campaign for Sustainable Rx Pricing in support of policy principles designed to help find solutions to high drug prices. These solutions seek to preserve innovation and ensure affordability by increasing transparency, promoting competition and realizing more value. Rising drug prices, their impact and implications are also on the agenda next week at the AHA’s Annual Meeting as the focus of a May 2 Executive Briefing. The time for action is now. As much as anyone, the women and men who work in hospitals recognize the value of innovative, lifesaving medicines but a drug priced beyond our – or a patient’s reach – cannot save anyone’s life. 

Related News Articles

Headline
White House Domestic Policy Council Director Neera Tanden spoke to Annual Meeting attendees about the environment hospitals and health systems are facing and…
Headline
The Federal Trade Commission and Department of Health and Human Services Feb. 14 requested comments for 60 days on market concentration and contracting…
Headline
The Department of Health and Human Services, Department of Justice, and Federal Trade Commission Dec. 7 announced several new actions to promote…
Headline
The companies that make the first 10 Medicare Part D drugs selected to participate in the Medicare Drug Price Negotiation Program have agreed to participate in…
Headline
The Food and Drug Administration will accept comments through Nov. 17 on draft guidance for labeling proposed biosimilar and interchangeable biosimilar…
Headline
A new Centers for Medicare & Medicaid Services fact sheet reviews how the agency selected the first 10 Part D drugs to include in the Medicare Drug Price…